Universal reference book for medicines
Product name: OXYTOCIN-FERIN (OXYTOCIN-FEREIN)

Active substance: oxytocin

Type: Tonicity and contractile activity of myometrium

Manufacturer: БРЫНЦАЛОВ-А (Russia)
Composition, form of production and packaging
The solution for intravenous and / or injection is
clear, colorless, with the odor of chlorobutanol hydrate.

1 ml

oxytocin 5 IU

Excipients: chlorobutanol hemihydrate, water d / u, acetic acid 1M.

1 ml - ampoules (5) - packings of cellular contour (1) - packs cardboard.

1 ml - ampoules (5) - packings the cellular contour (2) - packs cardboard.

1 ml - ampoules (5) complete with a knife ampoule or scarifier - packs cardboard.

1 ml - ampoules (10) complete with a knife ampoule or scarifier - packs cardboard.

INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2012.

PHARMACHOLOGIC EFFECT

Oxytocin - a synthetic analogue of the peptide hormone of the posterior lobe of the pituitary gland - stimulates the contraction of the smooth muscles of the uterus (especially the pregnant one) and myoepithelial cells of the mammary gland.

Oxytocin has a weak antidiuretic effect and in therapeutic doses does not significantly affect blood pressure.

The effect occurs in 1-2 minutes with subcutaneous and intramuscular injection, lasts for 20-30 minutes;
at intravenous introduction - through 0,5-1 minutes.
PHARMACOKINETICS

Рў 1/2 - 1-6 minutes (decreases on late terms of pregnancy and during lactation).
The connection with plasma proteins is low (30%).
Metabolised in the liver and kidneys.
During pregnancy in plasma, target organs, placenta, the content of oxytocinase inactivating the endogenous and exogenous oxytocin increases. Excretion, mainly by the kidneys in unchanged form.
INDICATIONS

- stimulation and stimulation of labor;

- prevention and treatment of hypotonic uterine bleeding in the early postpartum period;

- acceleration of postpartum involution of the uterus;

- strengthening the contractile capacity of the uterus in cesarean section (after removal of the afterbirth).

DOSING MODE

Oxytocin-FereinВ® is administered iv, in / m, into the wall or vaginal part of the cervix.

To initiate delivery, 0.5-2.0 IU oxytocin is administered in the m / m;
if necessary, repeat the injection every 30-60 minutes.
For intravenous drip injection, dilute 1 ml of the drug (5 ME) in 500 ml of a 5% dextrose solution.
Introduction begins with 5-8 drops / min, with the subsequent increase in speed depending on the nature of labor activity, but not more than 40 drops / min. During the infusion, constant monitoring of uterine activity and fetal heart rate is necessary.
For prophylaxis of hypotonic uterine bleeding, Oxytocin-FereinВ® is given intravenously 3-5 ME 2-3 times / day daily for 2-3 days, and for treatment of hypotonic uterine bleeding 5-8 ME are administered 2-3 times a day in for 3 days.
When cesarean section (after removal of the afterbirth) is introduced into the wall of the uterus at a dose of 3-5 ME.
SIDE EFFECT

Possible arrhythmia and bradycardia (in the mother and fetus), a decrease or increase in blood pressure, shock, subarachnoidal bleeding, nausea, vomiting, neonatal jaundice, a decrease in fetinogen content in the fetus, allergic reactions, bronchospasm, water retention, excessively active labor that may cause acute fetal hypoxia, premature detachment of the normally located placenta, rupture of the uterus.
If symptoms of these complications appear, discontinue the drug immediately.
CONTRAINDICATIONS

- increased individual sensitivity to the drug;

- arterial hypertension;

- kidney failure;

- predisposition to rupture of the uterus;

- inconsistency of the pelvis of the mother and fetus (narrow pelvis anatomical and clinical);

- transverse or oblique position of the fetus;

- premature birth;

- threatening rupture of the uterus;

- the presence of scars after a previous cesarean section or other operations on the uterus;

- excessive stretching of the uterus, uterus after multiple births;

- uterine septicemia;

- invasive cervical carcinoma;

- hypertension of the uterus (which did not arise during childbirth),

- fetal compression, intrauterine hypoxia of the fetus;

- Suspicion of premature detachment of the placenta, placenta previa.

PREGNANCY AND LACTATION

The drug is used for childbirth on strict indications.

APPLICATION FOR FUNCTIONS OF THE LIVER

Contraindicated in renal failure.

SPECIAL INSTRUCTIONS

Apply only under the supervision of a doctor in a hospital under the control of the contractile activity of the uterus, the condition of the fetus, blood pressure and the general condition of the woman.

OVERDOSE

Symptoms: hyperstimulation of the uterus, which can lead to hypertonia and tetanic contractions of the uterus, which, in turn, can lead to rupture of the uterus, postpartum hemorrhage, various changes in cardiac fetal activity, hypoxia and fetal death;
contraction of the fetus, fetal asphyxia, fetal bradycardia, uteroplacental hypoperfusion, hypoxia, hypercapnia, birth injuries of the fetus, water intoxication, convulsions.
Treatment: Immediately stop the introduction of the drug, reduce the injection of fluid, force diuresis, introduce symptomatic drugs and hypertensive saline solutions (to normalize the electrolyte balance), barbiturates (with caution).
Careful observation is necessary for the patient.
DRUG INTERACTION

Use with caution in combination with sympathomimetics (potentiates pressor action of sympathomimetics).
In combination with monoamine oxidase inhibitors, the risk of increasing blood pressure increases. Halothane and cyclopropane increase the risk of developing arterial hypotension.
TERMS OF RELEASE FROM PHARMACY

On prescription.

TERMS AND CONDITIONS OF STORAGE

List B. Store in a place protected from light and inaccessible to children at a temperature of 8 to 20 В° C.

Shelf life - 2 years.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!